Showing 4001-4010 of 5623 results for "".
- Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date for Pegcetacoplan for GAhttps://modernod.com/news/apellis-announces-fda-acceptance-of-nda-amendment-and-new-pdufa-date-of-february-26-2023-for-pegcetacoplan-for-ga/2481252/Apellis Pharmaceuticals announced that the FDA has accepted Apellis’ unsolicited major amendment to the new drug application (NDA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The updated Prescription D
- GenSight Biologics Announces Publication of Results of Lumevoq REFLECT Pivotal Clinical Trialhttps://modernod.com/news/gensight-biologics-announces-publication-of-results-of-lumevoq-reflect-pivotal-clinical-trial/2481250/GenSight Biologics announced that the neurology journal BRAIN has published efficacy and safety findings at 1.5-year post-treatment in ND4-LHON patients treated with lenadogene nolparvovec (Lumevoq) from the REFLECT pivotal clinical trial. The REF
- Azura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunctionhttps://modernod.com/news/azura-ophthalmics-announces-positive-results-from-phase-2b-clinical-trial-of-azr-md-001-in-meibomian-gland-dysfunction/2481247/Azura Ophthalmics announced positive 3-month efficacy and safety results from its phase 2b study of AZR-MD-001 0.5% in Meibomian Gland Dysfunction (MGD). The trial met its co-primary endpoints of improvements in Meibomian Glands Yielding Liquid Secretion (MGYLS; number of open glands) and Oc
- Heru Surpasses Clinical Milestone of 100,000 Eyes Examinedhttps://modernod.com/news/heru-surpasses-clinical-milestone-of-100000-eyes-examined/2481242/Heru announced that it has passed the clinical milestone of over 100,000 patient eyes that have been examined using its wearable technology since the company’s commercial launch a little over a year ago. “We are thrilled to see the rapid adoption of the Heru platform,&r
- Nidek Launches the NT-1p Non-Contact Tono/Pachymeterhttps://modernod.com/news/nidek-launches-the-nt-1p-non-contact-tonopachymeter/2481241/Nidek announced the launch of the NT-1p Non-Contact Tono/Pachymeter. The NT-1p is an innovative device that fully automates reliable non-contact tonometry and pachymetry. By placing the chin on the chinrest, the NT-1p automatically detects the position of the eyes and begins measurement without p
- Luminopia Announces Oversubscribed Seed Extension Financing Round to Fund Amblyopia Treatmenthttps://modernod.com/news/luminopia-announces-oversubscribed-seed-extension-financing-round-to-fund-amblyopia-treatment/2481237/Luminopia, a prescription digital therapeutics company developing a new class of treatments for neuro-visual disorders, announced an oversubscribed $5.7M seed extension financing round. The company will be using the funding for a staged rollout of its lead product for amblyopia to pediatric
- Harrow Launches Atropine.comhttps://modernod.com/news/harrow-launches-atropinecom/2481236/Harrow announced the launch of atropine.com, an ordering and marketing portal designed specifically for prescribers interested in compounded atropine formulations. All atropine.com, prescriptions will be dispensed through Harrow’s wholly owned
- Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX in Wet AMD Patientshttps://modernod.com/news/clearside-biomedical-announces-positive-results-in-safety-durability-and-biologic-effect-in-oasis-phase-12a-clinical-trial-of-suprachoroidal-cls-ax-in-wet-amd-patients/2481234/Clearside Biomedical announced positive results from its OASIS phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector in wet age-related macular degeneration (AMD) patients. Trial results include f
- Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-plans-to-submit-24-month-phase-3-data-to-the-fda-for-pegcetacoplan-nda-for-geographic-atrophy-ga/2481233/Apellis Pharmaceuticals provided an update on its new drug application (NDA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The company plans to submit the 24-month efficacy data from the phase 3 DERB
- Kinarus Therapeutics Provides Strategic Updatehttps://modernod.com/news/kinarus-therapeutics-provides-strategic-update/2481226/Kinarus Therapeutics reiterated its plans to focus on clinical trials in wet age-related macular degeneration (AMD) and idiopathic pulmonary fibrosis, and to refocus its capital resources and financing efforts to drive these programs. Following the discontinuation of the phase 2 KINETIC